Toronto, ON, January 29, 2013 – iGan Partners is pleased to announce an investment in Imagistx Inc. This first round of financing, led by iGan Partners with participation from a group of private investors, will be used by Imagistx to conduct multi-site clinical trials and to further enhance its leading prostate ultrasound imaging system.
Imagistx uses ultra high frequency ultrasound technology that will dramatically improve prostate cancer detection rates over the current standard of care. It will also provide valuable monitoring tools for prostate cancer, supporting a growing trend towards active surveillance. Important technology used by Imagistx was contractually developed by FUJIFILM VisualSonics, Inc., the world’s leader in high-resolution ultrasound technology. Their advanced technology, over the past 3 years, has been adapted to work on the prostate and Imagistx has the worldwide exclusive rights to use important FUJIFILM VisualSonics, Inc. high-resolution ultrasound technology for prostate imaging.
“We are excited with this new investment made in Imagistx, and we value our relationship with iGan Partners, who has played an instrumental role in structuring the transaction and the financing. This new funding will allow us to perform clinical trials that will conclusively demonstrate that ultra high frequency ultrasound is a game changer for prostate cancer detection and management.” said Randy AuCoin, COO of Imagistx.
“We have invested a lot of time and effort in structuring the company and negotiating strong agreements that are the backbone of this company’s enormous potential. We are confident that Imagistx will be very successful for investors and revolutionize the way prostate cancer is detected and treated” said Sam Ifergan, President of iGan Partners.
Imagistx has developed an ultra high resolution ultrasound system that provides significant improvements in detecting prostate cancer. It’s ultrasound system allows urologists to see the exquisite details of the prostate, allowing for better diagnosis, surveillance, and treatment. For more information, please visit www.imagistxprostate.com